Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain
Luisa Martinez-pomares
Journal of Allergy and Clinical Immunology, 2012
View PDFchevron_right
Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation
Roseline d'Oiron
Haematologica-the Hematology Journal, 2008
View PDFchevron_right
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors
Ana Navarrete
Blood, 2007
View PDFchevron_right
Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells
B. Wootla
Haemophilia, 2007
View PDFchevron_right
Enhanced uptake of blood coagulation factorVIIIcontaining immune complexes by antigen presenting cells
Edith Slot
Journal of Thrombosis and Haemostasis, 2017
View PDFchevron_right
Inhibitors in haemophilia A: the role of VWF/FVIII concentrates - a meeting report
Alessandro Gringeri
Haemophilia, 2009
View PDFchevron_right
Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells
M. Ozelo
Journal of Thrombosis and Haemostasis, 2008
View PDFchevron_right
Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products
Tom Howard
Blood Advances, 2019
View PDFchevron_right
Intravenous administration of Factor VIII–O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein
Sathy Balu-iyer
European Journal of Pharmaceutical Sciences, 2015
View PDFchevron_right
Immune Complexes Enhance Uptake of Blood Coagulation Factor VIII by Antigen Presenting Cells
Jan Voorberg
Blood, 2012
View PDFchevron_right
Potency and mass of factor VIII in FVIII products
Saulius Butenas
Haemophilia, 2009
View PDFchevron_right
Production and characterization of polyclonal antibodies to human recombinant domain B-free antihemophilic factor VIII
Victor Nedzvetsky
Europe PMC (PubMed Central), 2017
View PDFchevron_right
The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro
Frederick Ofosu
Haemophilia, 2012
View PDFchevron_right
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor
Roseline d'Oiron
View PDFchevron_right
Quantitative HLA‐class‐II/Factor VIII (FVIII) Peptidomic Variation in Dendritic Cells Correlates with the Immunogenic Potential of Therapeutic FVIII Proteins in Hemophilia A
Huy Huynh
Journal of Thrombosis and Haemostasis
View PDFchevron_right
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects
Carla Valsecchi
TH Open
View PDFchevron_right
Structure of Blood Coagulation Factor VIII in Complex with an Anti-C1 Domain Pathogenic Antibody Inhibitor
Lexi Jarvis
2020
View PDFchevron_right
Dangerous liaisons: how the immune system deals with factor VIII
Jan Voorberg, Aleksandra Wroblewska
Journal of Thrombosis and Haemostasis
View PDFchevron_right
Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII
P. Nurden
Journal of Thrombosis and Haemostasis, 2003
View PDFchevron_right
Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice
Aleksandra Wroblewska
Blood, 2012
View PDFchevron_right
Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance
Grancha Grancha, Bastian Zimmermann
Haemophilia, 2012
View PDFchevron_right
Cellular uptake of coagulation factor VIII: Elusive role of the membrane-binding spikes in the C1 domain
Lydia Castro
The International Journal of Biochemistry & Cell Biology, 2017
View PDFchevron_right
Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A
Ana Navarrete
Haematologica-the Hematology Journal, 2007
View PDFchevron_right
presentation to immune effectors VWF protects FVIII from endocytosis by dendritic cells and subsequent
Ana Navarrete
2010
View PDFchevron_right
Activation, activity and inactivation of factor VIII in factor VIII products
Saulius Butenas
Haemophilia, 2016
View PDFchevron_right
Factor VIII Hemophilia A Inactivate Therapeutic Catalytic IgG from Patients with
Johan Hoebeke
2000
View PDFchevron_right
Use of recombinant factor VIII in the management of hemophilia
marco cattaneo
Current studies in hematology and blood transfusion, 1991
View PDFchevron_right
Biological considerations of plasma-derived and recombinant factor VIII immunogenicity
Julie Tarrant
Blood, 2017
View PDFchevron_right
The use of recombinant factor VIII in the management of Hemophilia
Alessandro Gringeri
La Ricerca in Clinica e in Laboratorio, 1991
View PDFchevron_right